{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:21:30Z","timestamp":1790842890000,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2010K34C45_008"],"award-info":[{"award-number":["2010K34C45_008"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jcyt.2015.10.014","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T11:18:35Z","timestamp":1450437515000},"page":"278-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G\u2013opsonized target cells"],"prefix":"10.1016","volume":"18","author":[{"given":"Maria Michela","family":"D'Aloia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Caratelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Battella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Arriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sconocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Alimandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2015.10.014_bib0010","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","article-title":"Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape","volume":"28","author":"Ferris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd3365","article-title":"Advances in the assessment and control of the effector functions of therapeutic antibodies","volume":"10","author":"Jiang","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0020","first-page":"373","article-title":"Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer","volume":"382","author":"Bakema","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ymeth.2013.06.020","article-title":"Myeloid cells as effector cells for monoclonal antibody therapy of cancer","volume":"65","author":"Braster","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1359-6446(03)02714-4","article-title":"Renaissance of cancer therapeutic antibodies","volume":"8","author":"Glennie","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12026-014-8542-z","article-title":"Complement in monoclonal antibody therapy of cancer","volume":"59","author":"Rogers","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0040","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-014-0080-8","article-title":"Dual roles for immune metagenes in breast cancer prognosis and therapy prediction","volume":"6","author":"Alistar","year":"2014","journal-title":"Genome Med"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fimmu.2013.00481","article-title":"Combination immune therapies to enhance anti-tumor responses by NK cells","volume":"4","author":"Mentlik James","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0055","first-page":"279","article-title":"Role of natural killer cells in cancer","volume":"12","author":"Pross","year":"1993","journal-title":"Nat Immun"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0060","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/0008-5472.CAN-11-2544","article-title":"Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity","volume":"72","author":"Pietra","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0065","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1593\/neo.09296","article-title":"Defective infiltration of natural killer cells in MICA\/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction","volume":"11","author":"Sconocchia","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0070","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/0008-5472.CAN-12-1181","article-title":"Melanoma cells inhibit NK cell functions","volume":"72","author":"Sconocchia","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/CritRevOncog.2014011142","article-title":"NK cells in the tumor microenvironment","volume":"19","author":"Larsen","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0080","doi-asserted-by":"crossref","first-page":"e952197","DOI":"10.4161\/21624011.2014.952197","article-title":"NK cells and T cells cooperate during the clinical course of colorectal cancer","volume":"3","author":"Sconocchia","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0085","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-012-1231-7","article-title":"Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer","volume":"61","author":"Liu","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0090","first-page":"1115","article-title":"Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy","volume":"34","author":"Melichar","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.molimm.2014.12.009","article-title":"Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic","volume":"67","author":"Duong","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc gamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0105","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2005-09-3775","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes","volume":"107","author":"Cl\u00e9menceau","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2326-6066.CIR-13-0099-T","article-title":"Gene-modified human \u03b1\/\u03b2-T cells expressing a chimeric CD16-CD3\u03b6 receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy","volume":"2","author":"Ochi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/icb.2010.37","article-title":"Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo","volume":"88","author":"Janssen","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2567.2009.03072.x","article-title":"Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo","volume":"128","author":"Meiraz","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0130","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1158\/0008-5472.CAN-09-0685","article-title":"Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity","volume":"69","author":"Shanker","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0135","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.4049\/jimmunol.167.9.5042","article-title":"CD8(+) tumor-infiltrating cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis","volume":"167","author":"Radoja","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0140","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1073\/pnas.78.4.2502","article-title":"Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro","volume":"78","author":"Kaufmann","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s002620050532","article-title":"Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes","volume":"47","author":"Haynes","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0150","first-page":"14","article-title":"High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV\/retroviral vector expressing the green fluorescence protein","volume":"58","author":"Grignani","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0155","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1073\/pnas.90.17.8033","article-title":"Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non mammalian cells","volume":"90","author":"Burns","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0160","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.1073\/pnas.91.20.9564","article-title":"A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes","volume":"91","author":"Yee","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0165","first-page":"1138","article-title":"Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex","volume":"15","author":"Schoof","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0170","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/79774","article-title":"The 21- and 23-kD forms of TCR zeta are generated by specific ITAM phosphorylations","volume":"1","author":"van Oers","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0175","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1128\/MCB.20.18.6945-6957.2000","article-title":"Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation","volume":"20","author":"Shan","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0180","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0185","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0190","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273","article-title":"Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction","volume":"100","author":"Uherek","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0195","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.4049\/jimmunol.159.8.3849","article-title":"Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding","volume":"159","author":"Edberg","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0200","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ni.2941","article-title":"Serine-threonine kinases in TCR signaling","volume":"15","author":"Navarro","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0205","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/eji.200635929","article-title":"Duration of CTL activation regulates IL-2 production required for autonomous clonal expansion","volume":"36","author":"Spierings","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0210","doi-asserted-by":"crossref","first-page":"22307","DOI":"10.1074\/jbc.272.35.22307","article-title":"Activation-induced aggregation and processing of the human Fas antigen. Detection with cytoplasmic domain-specific antibodies","volume":"272","author":"Kamitani","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0215","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0220","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1189\/jlb.72.4.668","article-title":"Hepatic natural killer cells exclusively kill splenic\/blood natural killer-resistant tumor cells by the perforin\/granzyme pathway","volume":"72","author":"Vermijlen","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1476-4598-13-219","article-title":"Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects","volume":"13","author":"Shi","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0230","doi-asserted-by":"crossref","first-page":"22ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PPO.0000000000000034","article-title":"CD28z CARs and armored CARs","volume":"20","author":"Pegram","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0240","first-page":"127","article-title":"Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity","volume":"21","author":"Gross","year":"1989","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0250","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/ijc.25960","article-title":"Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling","volume":"129","author":"Hombach","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0255","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PPO.0000000000000028","article-title":"4-1BB chimeric antigen receptors","volume":"20","author":"Campana","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0260","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-8722-6-33","article-title":"Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma","volume":"6","author":"Shen","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0270","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0275","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0280","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0285","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0290","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0295","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0300","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.4049\/jimmunol.161.12.6604","article-title":"Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit","volume":"161","author":"Annekov","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0305","first-page":"1116","article-title":"An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30","volume":"58","author":"Hombach","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0310","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V90.2.716","article-title":"Signaling pathways regulating CD44-dependent cytolysis in natural killer cells","volume":"2","author":"Sconocchia","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.10.014_bib0315","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324915011196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324915011196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:22:11Z","timestamp":1761430931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324915011196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1465324915011196"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2015.10.014","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G\u2013opsonized target cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2015.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}